Revenue reached $216.3M in 2026Q3 with gross margin recovering to 58.0% and operating margin to 11.9%, yet net income swung from -$15.1M in 2026Q2 to $21.8M, suggesting earnings remain highly sensitive to quarterly swings.
Collegium Pharmaceutical, Inc. (COLL) annual income statement — 13-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | 815.19M | 780.57M | 631.45M | 566.77M | 463.93M | 276.87M | 310.02M | 296.7M | 280.41M | 28.48M | 1.71M | 0 | 0 | 0 |
| Revenue Growth % | 7.68% | 23.62% | 11.41% | 22.17% | 67.56% | -10.69% | 4.49% | 5.81% | 884.73% | 1564.29% | - | - | - | - |
| Cost of Goods Sold | 333.85M | 317.31M | 254.1M | 240.6M | 254.44M | 126.25M | 130.18M | 193.66M | 165.68M | 2.6M | 213K | 171K | 0 | 0 |
| COGS % of Revenue | - | 40.65% | 40.24% | 42.45% | 54.85% | 45.6% | 41.99% | 65.27% | 59.08% | 9.11% | 12.45% | - | - | - |
| Gross Profit | 481.33M | 463.26M | 377.34M | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.5M | -171K | 0 | 0 |
| Gross Margin % | 59.05% | 59.35% | 59.76% | 57.55% | 45.15% | 54.4% | 58.01% | 34.73% | 40.92% | 90.89% | 87.55% | - | - | - |
| Gross Profit Growth % | - | 22.77% | 15.69% | 55.7% | 39.09% | -16.25% | 74.53% | -10.19% | 343.32% | 1627.7% | 976.02% | - | - | - |
| Operating Expenses | 360.62M | 276.17M | 207.45M | 159.21M | 176.17M | 132.99M | 123.6M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.66M | 16.04M |
| OpEx % of Revenue | - | 35.38% | 32.85% | 28.09% | 37.97% | 48.03% | 39.87% | 42.73% | 48.29% | 355.84% | 5586.21% | - | - | - |
| Selling, General & Admin | 273.82M | 276.17M | 182.98M | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
| SG&A % of Revenue | - | 35.38% | 28.98% | 28.09% | 37.11% | 42.97% | 36.72% | 39.25% | 45.2% | 325.73% | 4712.57% | - | - | - |
| Research & Development | 0 | 0 | 0 | 0 | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.97M | 14.96M | 14.16M |
| R&D % of Revenue | - | - | - | - | 0.86% | 3.41% | 3.15% | 3.48% | 3.09% | 30.1% | 873.64% | - | - | - |
| Other Operating Expenses | 2M | 0 | 24.47M | 0 | 0 | 4.58M | 0 | 0 | 0 | 0 | -94K | 0 | 0 | 0 |
| Operating Income | 120.71M | 187.08M | 169.9M | 166.96M | 33.32M | 17.63M | 56.23M | -23.75M | -20.68M | -75.45M | -94.08M | -26.91M | -17.66M | -16.04M |
| Operating Margin % | 14.81% | 23.97% | 26.91% | 29.46% | 7.18% | 6.37% | 18.14% | -8% | -7.38% | -264.95% | -5498.66% | - | - | - |
| Operating Income Growth % | - | 10.12% | 1.76% | 401.1% | 89.01% | -68.65% | 336.79% | -14.81% | 72.58% | 19.81% | -249.66% | -52.32% | -10.12% | - |
| EBITDA | 302.01M | 413.16M | 339.06M | 316.22M | 172.26M | 86.55M | 117.78M | -8.27M | 90.22M | -74.85M | -93.43M | -26.74M | -17.48M | -15.87M |
| EBITDA Margin % | 37.05% | 52.93% | 53.69% | 55.79% | 37.13% | 31.26% | 37.99% | -2.79% | 32.17% | -262.86% | -5460.37% | - | - | - |
| EBITDA Growth % | -21.5% | 21.86% | 7.22% | 83.57% | 99.04% | -26.52% | 1525.07% | -109.16% | 220.53% | 19.88% | -249.44% | -52.97% | -10.11% | - |
| D&A (Non-Cash Add-back) | 177.28M | 226.07M | 169.16M | 149.26M | 138.94M | 68.92M | 61.55M | 15.48M | 110.91M | 594K | 655K | 171K | 187K | 169K |
| EBIT | 204.27M | 174.93M | 172.54M | 159.07M | 34.37M | 17.64M | 56.46M | -21.81M | -19M | -74.86M | -94.08M | -26.82M | -17.66M | -16.12M |
| Net Interest Income | -151.43M | -71.02M | -60M | -67.72M | -62.17M | -21M | -28.65M | 1.03M | -18.44M | 582K | -94K | 0 | 0 | 0 |
| Interest Income | 10.69M | 11.29M | 13.98M | 15.62M | 1.05M | 12K | 232K | 1.94M | 1.69M | 582K | 0 | 0 | 0 | 0 |
| Interest Expense | 162.12M | 82.31M | 73.97M | 83.34M | 63.21M | 21.01M | 28.88M | 909K | 20.13M | 0 | 94K | 439K | 252K | 76K |
| Other Income/Expense | -78.56M | -94.47M | -71.33M | -91.23M | -62.17M | -21M | -28.65M | 1.03M | -18.44M | 582K | -94K | -348K | -252K | -155K |
| Pretax Income | 42.15M | 92.62M | 98.57M | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.2M |
| Pretax Margin % | 5.17% | 11.87% | 15.61% | 13.36% | -6.22% | -1.22% | 8.9% | -7.66% | -13.95% | -262.91% | -5504.15% | - | - | - |
| Income Tax | 3.98M | 29.75M | 29.38M | 27.58M | -3.85M | -74.89M | 830K | 0 | 0 | 0 | 94K | -91K | 0 | 79K |
| Effective Tax Rate % | 9.45% | 32.12% | 29.8% | 36.41% | 13.33% | 2219.65% | 3.01% | 0% | 0% | 0% | -0.1% | 0.33% | 0% | -0.49% |
| Net Income | 38.17M | 62.87M | 69.19M | 48.16M | -25M | 71.52M | 26.75M | -22.72M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.2M |
| Net Margin % | 4.68% | 8.05% | 10.96% | 8.5% | -5.39% | 25.83% | 8.63% | -7.66% | -13.95% | -262.91% | -5504.15% | - | - | - |
| Net Income Growth % | -34.69% | -9.13% | 43.68% | 292.6% | -134.96% | 167.33% | 217.74% | 41.93% | 47.74% | 20.51% | -245.54% | -52.12% | -10.62% | - |
| Net Income (Continuing) | 38.17M | 62.87M | 69.19M | 48.16M | -25M | 71.52M | 26.75M | -22.72M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.98 | 1.73 | 1.86 | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| EPS Growth % | -37.64% | -6.99% | 44.19% | 274.32% | -139.78% | 144.74% | 416.67% | 79.83% | 51.82% | 36.34% | -93.03% | 16.25% | -10.6% | - |
| EPS (Basic) | - | 1.98 | 2.14 | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| Diluted Shares Outstanding | 39.11M | 39.7M | 40.42M | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Basic Shares Outstanding | 31.73M | 31.71M | 32.27M | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying COLL stock.
For fiscal year 2025, Collegium Pharmaceutical, Inc. (COLL) reported total revenue of $780.6M.
Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $62.9M in net income for the fiscal year ending 2025 with a net profit margin of 8.1%.
Collegium Pharmaceutical, Inc. (COLL) reported an operating income of $187.1M, resulting in an operating profit margin of 24.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Collegium Pharmaceutical, Inc. (COLL) generated $463.3M in gross profit for the year, representing a gross profit margin of 59.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Leverage Constrains Revenue Shortfall Tolerance
Metrics are mathematically derived from official filings.
Revenue Growth Decelerates Toward Single Digits
According to reported quarterly figures, Collegium's revenue rose 3.3% year over year to $216.3M in 2026Q3, a sharp deceleration from the 31.4% growth reported in 2025Q3 and suggesting the earlier expansion is maturing.
The reported figures suggest growth has moved from a high-teens-to-thirties pace in 2024 and 2025 toward a low single-digit rate, with 2026Q2 revenue actually declining 7.5% in net income terms despite 6.3% top-line growth. The mix of volume and pricing behind this slowdown is not disclosed in the supplied data, so it is unclear whether ADHD franchise momentum is fading or simply normalizing. Investors should monitor whether sequential revenue gains resume, as a sustained low-single-digit trajectory would weaken the case that the company is in a durable growth phase.
Gross Margin Recovers but Stays Below Peers
Based on reported income statement figures, Collegium's gross margin reached 58.0% in 2026Q3, recovering from 55.2% in 2026Q2, yet still trailing the roughly 77% to 80% gross margins reported for peers Harmony Biosciences and Supernus.
The persistent gap with peers appears consistent with the royalty burden and gross-to-net adjustments embedded in the Nucynta and Xtampza ER economics, which structurally cap the margin ceiling. The recent recovery is encouraging but has not yet returned to the 62% to 63% levels seen in late 2024 and late 2025, suggesting mix or pricing pressure has not fully reversed. Without the breakdown of royalty tiers and rebate rates, the drivers of the swing cannot be confirmed, so the margin trend should be treated as directional.
Net Income Volatility Obscures Underlying Earnings
As reported in financial statements, Collegium posted net income of -$15.1M in 2026Q2 against $21.8M in 2026Q3, and EPS swung from a $0.07 low in 2025Q1 to $0.84 in 2025Q3, signaling earnings that are highly sensitive to quarterly accruals.
The wide range in net income relative to operating income suggests that below-the-line items, including amortization of acquired intangibles and tax provision effects from NOL utilization, are contributing materially to reported results. Stock-based compensation of roughly $10M to $14M per quarter is modest but still represents a recurring non-cash charge that should be considered when assessing cash earnings power. The recent EPS miss of $1.96 against a $1.98 consensus is marginal, but the pattern of quarterly swings argues against relying on any single period as a reliable run-rate.
Operating Leverage Reverses in Recent Quarters
Based on reported figures, Collegium's operating margin fell from 28.8% in 2025Q4 to 1.9% in 2026Q2 before recovering to 11.9% in 2026Q3, with SG&A of $106.6M in 2026Q2 outpacing revenue growth.
The reported SG&A trend indicates that the company's commercial cost base has not been scaling efficiently with revenue, which reverses the operating leverage seen in 2024 when operating margin reached 32.7%. The 2026Q3 recovery suggests cost discipline may be returning, but the margin remains well below prior-year levels and below the roughly 21% to 24% operating margins reported for peers. Investors should monitor whether SG&A growth can be held below revenue growth going forward.
Leverage Limits Room for Execution Errors
Based on reported figures, Collegium's debt-to-equity ratio of 3.12 and a net margin of 8.1% leave limited cushion if revenue growth stalls further or opioid-related production quotas tighten.
The reported leverage suggests balance sheet sensitivity is high, and a further EPS shortfall or guidance revision could pressure debt servicing capacity and reduce flexibility for acquisitions meant to diversify away from the opioid franchise. The combination of decelerating growth and volatile quarterly earnings may indicate that the market's valuation depends more heavily on sustained ADHD volume conversion than the current headline numbers alone can confirm. This analysis is inferential, and the supplied data does not disclose debt maturities or covenant terms that would determine the actual level of risk.